Do you want to read an article? Please log in or register.
Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Related content
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
JAMA Intern Med.
Gooding HC, Ning H, Gillman MW, Shay C, Allen N, Goff DC Jr, Lloyd-Jones D, Chiuve S
doi: 10.1001/
RECOMMENDED
Cardiovascular Risk and Diseases
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
doi: 10.1016/S0140-6736(21)01122-3
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Lancet Diabetes Endocrinol.
Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA
doi: 10.1016/S2213-8587
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey
Eur Heart J.
Banach M, Mazidi M, Mikhailidis DP, Toth PP, Jozwiak J, Rysz J, Watts GF
doi: 10.1093/eurheartj/ehy527.
Cardiac Arrest or DeathHeart, Artery and Coronary Diseases
Clinical Yield of Familial Screening After Sudden Death in Young Subjects: The French Experience
Circ Arrhythm Electrophysiol.
Quenin P, Kyndt F, Mabo P, Mansourati J, Babuty D, Thollet A, Guyomarch B, Redon R, Barc J, Schott JJ, Sacher F, Probst V, Gourraud JB
doi: 10.1161/CIRCEP.117.005236.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Pharmacoeconomics.
Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N, Wierzbicki AS
doi: 10.1007/s40273
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial InfarctionThrombosis and Stroke
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
JAMA.
Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K.
doi: 10.1001/jama.2016.11004.
Cardiovascular Risk and Diseases
Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System
JAMA Cardiol.
Modi ZJ, Lu Y, Ji N, Kapke A, Selewski DT, Dietrich X, Abbott K, Nallamothu BK, Schaubel DE, Saran R, Gipson DS
doi: 10.1001/jamacardio.
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia
Eur Heart J.
Tada H,Kawashiri M, Nohara A, Inazu A, Mabuchi H, Yamagishi M
doi: 10.1093/eurheartj/ehx004.